Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.

Trial Details

NCT ID
NCT05803941
Phase
PHASE4
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • AAA617
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Orange, California, United States|33.78779,-117.85311
  • Santa Monica, California, United States|34.01949,-118.49138
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Hartford, Connecticut, United States|41.76371,-72.68509

Key Eligibility Criteria

  • Signed informed consent must be obtained prior to participation in the study
  • Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have f…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →